DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
09 janv. 2024 08h00 HE
|
Daxor Corporation
Patent Covers Systems and Methods For Algorithmic Treatment Across a Spectrum of Conditions Oak Ridge, TN, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
02 janv. 2024 08h30 HE
|
Daxor Corporation
The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global...
New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
23 mars 2023 08h30 HE
|
Daxor Corporation
Commonly Used Pressure Measure for Volume Assessment Discordant with Direct Measurement by BVA Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in...
Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients
23 mars 2023 08h00 HE
|
Daxor Corporation
BVA Feasibly Guides Fluid Management with Greater Accuracy than Traditional MeansResearchers Conclude that a Larger Powered RCT is Warranted Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor...
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
12 mai 2022 08h00 HE
|
Daxor Corporation
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
02 mai 2022 08h00 HE
|
Daxor Corporation
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
06 avr. 2022 08h00 HE
|
Daxor Corporation
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
23 mars 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
01 mars 2022 09h00 HE
|
Daxor Corporation
Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021
01 mars 2022 08h00 HE
|
Daxor Corporation
Revenues of Operating Division Increase by 70.6% Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed...